Results 61 to 70 of about 71,664 (187)

Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer

Medicinal Research Reviews, EarlyView.
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek, Jernej Cingl, Urša Pečar Fonović, Tihomir Tomašič   +3 more
wiley   +1 more source

Integrative Approaches in Cardiovascular Disease: The Role of Nutraceuticals in Heart Failure, Atrial Fibrillation, and Related Conditions

Phytotherapy Research, EarlyView.
Schematic representation of the shared pathophysiological mechanisms underlying heart failure (HF) and atrial fibrillation (AF), including inflammation, oxidative stress, endothelial dysfunction, and fibrosis. The figure highlights the clinical and mechanistic convergence of conventional pharmacological therapies and selected nutraceuticals in ...
Laura Beatrice Mattioli, Ivan Corazza, Roberta Budriesi, Luca Camarda, Maria Carelli, Alberto Spadotto, Igor Diemberger   +6 more
wiley   +1 more source

HER2‐Targeted AIE Nanotheranostics Overcome SHR‐A1811 Resistance via Immunogenic Pyroptosis and Tumor‐Associated Macrophage Reprogramming in Breast Cancer

Small, EarlyView.
HER2‐targeted AIE780‐A1811 nanoparticles self‐assemble via amide coupling of a mitochondria‐directed photosensitizer with the ADC SHR‐A1811. Upon 660 nm irradiation, they generate ROS, photothermal effects, and controlled drug release, inducing immunogenic pyroptosis and M2‐to‐M1 macrophage reprogramming. This dual action remodels the immunosuppressive
Xiaohong Liu, Nisha Wu, Zaihui Peng, Guozhi Zhang, Lin Ren, Qiuyun Li, Jie Xiao, Jing He, Yuxiuzi Xiao, Li Ma, Yi Zhang, Ying Gong, Xiaowei Qi   +12 more
wiley   +1 more source

Development of new radiopharmaceutical for molecular imaging in oncology [PDF]

, 2011
De afgelopen jaren zijn diverse nieuwe geneesmiddelen tegen kanker ontwikkeld. Er kan echter nog niet goed vooraf voorspeld worden bij welke patiënt deze nieuwe geneesmiddelen zullen werken.
Dijkers, Eli Carl Ferre,, Dijkers, Eli Carl Ferre   +1 more
core   +2 more sources

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells

, 2023
Tania Mariastella Caputo,1,* Giovannina Barisciano,2,* Chiara Mulè,1 Angela Maria Cusano,3 Anna Aliberti,1 Livio Muccillo,2 Vittorio Colantuoni,2 Lina Sabatino,2 Andrea Cusano1,3 1Optoelectronics Group, Department of Engineering, University of ...
Sabatino L, Muccillo L, Barisciano G, Caputo TM, Mulè C, Cusano AM, Cusano A, Colantuoni V, Aliberti A   +8 more
core  

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. [PDF]

, 2019
BACKGROUND HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms.
Bachelot, Thomas, Regan, Meredith M, Viale, Giuseppe, Jerusalem, Guy, Curigliano, Giuseppe, Kammler, Roswitha, Smyth, Mark J, Hui, Rina, Loi, Sherene, André, Fabrice, Biganzoli, Laura, Bartsch, Rupert, Di Leo, Angelo, Gombos, Andrea, Rabaglio, Manuela-Poretti, Colleoni, Marco, Campone, Mario, Bonnefoi, Hervé, Giobbie-Hurder, Anita, Maibach, Rudolf   +19 more
core   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of ⁶⁴Cu-Trastuzumab

, 2019
Immuno-positron emission tomography (immuno-PET) is expected to improve the specificity of small chemical tracers such as 18F-fluorodeoxyglucose. Whole antibodies significantly accumulate in target molecule-expressing tumors but frequently persist too ...
Shota Warashina (6274394), Kohta Mohri (1620718), Yasuhiro Wada (378641), Qin Ren (150436), Yasuyoshi Watanabe (15245), Hidefumi Mukai (6274397)   +5 more
core   +1 more source